ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 288

MRI Findings In Juvenile Spondyloarthopathy and Effects Of Treatment On Subsequent MRI

Clara Lin1 and Diana Milojevic2, 1Pediatric Rheumatology, University of California-San Francisco, San Francisco, CA, 2Dept of Pediatric Rheumatology, University of California, San Francisco, San Francisco, CA

Meeting: 2013 ACR/ARHP Annual Meeting

Keywords: MRI, pediatrics and spondylarthropathy

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Pediatric Rheumatology - Clinical and Therapeutic Aspects I: Juvenile Idiopathic Arthritis

Session Type: Abstract Submissions (ACR)

Background/Purpose: : The aim of our study was to

  • describe pelvic MRI findings of juvenile spondyloarthopathy
  • describe the treatment effects on subsequent MRIs in juvenile spondyloarthropathy
  • determine predictors of active sacroiliitis in children

Methods: This was a retrospective chart and imaging review of children ages 5 to 21 year old seen in the pediatric rheumatology clinic from 2009 to 2012 with a MRI of the sacroiliac joints (MRI-SI).  Data collected included demographics, patient’s history, physical exam, and laboratory results at each visit.  The pelvic joints (sacroiliac, hip, and facet)and entheses were reviewed on MRI-SI, and the sacroiliac joints were graded on a semi-quantitative scale (0-3) for bone marrow edema (BME), synovial enhancement, erosions to create a composite score ratio.

Results: 50 subjects with 76 MRI-SI were studied, and 32 subjects had sacroiliitis on 48 MRIs.  Of the subjects with sacroiliitis, mean age± standard deviation was 13.68±2.59 years, 71% were male and 41% were HLA-B27 positive.  In 22.9% of subjects with sacroiliitis, history and physical exam did not reveal signs of sacroiliitis. Inflammatory markers (ESR, CRP, WBC, Platelet count) were normal in 50% of cases of (+) sacroiliitis.  In 16.7% of cases of sacroiliitis (n=8) in 7 subjects, physical exam of SI joints, Modified Schober’s exam, and inflammatory markers were normal.  In subjects with sacroiliitis, MRI also revealed hip arthritis and pelvic enthesitis in 71.4%and 40.6% of exams, respectively.  Longitudinal data was available for 13 subjects.  MRI-SI composite score ratio improved in 8 subjects with the greatest improvement occurring with initiation of etanercept therapy.  Improvements in composite score ratio were due to improvement of BME and SE components, but erosion scores remained stable or worsened in all but 1 subject.

Conclusion: In our group of children with sacroiliitis, male:female ratio was 2.56 and HLA-B27 was present in 41% of subjects. Predicting active sacroiliitis from history, physical exam, and laboratory findings remains a challenge.  Hip arthritis and pelvic enthesitis were common findings in cases of sacroiliitis in children.  Greatest improvement of sacroiliitis on MRI was seen after initiating etanercept by decreasing bone marrow edema and synovial enhancement; however, erosions did not seem to improve on therapy.


Disclosure:

C. Lin,
None;

D. Milojevic,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2013 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/mri-findings-in-juvenile-spondyloarthopathy-and-effects-of-treatment-on-subsequent-mri/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology